An antibody therapy markedly reduces aggregates of amyloid-β, the hallmark protein of Alzheimer's disease, and might slow cognitive decline in patients. Confirmation of a cognitive benefit would be a game-changer. See Article p.50
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Notes
References
Selkoe, D. J. & Hardy, J. EMBO Mol. Med. 8, 595–608 (2016).
Sevigny, J. et al. Nature 537, 50–56 (2016).
Haass, C. & Selkoe, D. J. Nature Rev. Mol. Cell Biol. 8, 101–112 (2007).
Reiman, E. M. et al. Nature Rev. Neurol. 12, 56–61 (2016).
Fleisher, A. S. et al. JAMA Neurol. 72, 316–324 (2015).
Yu, J. Y. & Watts, R. J. Neurotherapeutics 10, 459–472 (2013).
Sperling, R. A. et al. Alzheimer's Dement. 7, 367–385 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.M.R. is a principal investigator of the Alzheimer’s Prevention Initiative (API), which is involved in the evaluation of anti-Aβ and other promising Alzheimer’s prevention therapies.
Related links
Rights and permissions
About this article
Cite this article
Reiman, E. Attack on amyloid-β protein. Nature 537, 36–37 (2016). https://doi.org/10.1038/537036a
Published:
Issue Date:
DOI: https://doi.org/10.1038/537036a